Amyris up after intranasal delivery of vaccine shows promise against COVID-19

Amyris

20/08/2021 13:46

** Shares of biotechnology firm Amyris Inc  AMRS.O  rise
4.8% to $12.72 premarket
    ** Says pre-clinical testing data shows its ribonucleic acid
(RNA) vaccine candidate when administered intranasally generates
antibodies and provides upper respiratory protection for
SARS-CoV-2  urn:newsml:reuters.com:*:nPn9R6lHTa
    ** The RNA vaccine is being developed in collaboration with
the Infectious Disease Research Institute, a nonprofit global
health organization
    ** Vaccine has potential to provide fuller protection
against current variants of SARS-CoV-2 and the intranasal
delivery technology can protect against SARS-CoV-2 and other
respiratory diseases, including the flu - AMRS
    ** If approved and commercialized, the vaccine is targeted
to be more accessible to people in underserved countries - AMRS
    ** Stock has gained ~96% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))